Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial
Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial
复制标题
DOI：
10.1007/s00213-006-0516-y
复制
发表时间：
2006-11-01
影响因子：
3.4
通讯作者：
Levin, Edward D.
中科院分区：
文献类型：
--
作者：
McClernon, F. Joseph;Hiott, F. Berry;Levin, Edward D.
基本原理尽管尼古丁依赖和抑郁症之间存在联系，但很少有研究探讨尼古丁对抑郁症症状的影响。目的本研究评估了尼古丁透皮贴剂对基线抑郁症状的非吸烟者在4周内的急性和慢性影响，方法从社区招募流行病学研究中心抑郁量表（CES-D）评分>= 10的非吸烟者。在基线（第0天）以及第1、8、21和28天测量情绪和认知表现。受试者被随机分配佩戴安慰剂或尼古丁贴片4周（第1周和第4周为3.5 mg/天;第2周和第3周为7 mg/天）。最终样本包括11名非吸烟者，平均基线CES-D评分为27.36（SD=10.53）。结果唾液尼古丁水平表明，大多数参与者都符合治疗。急性尼古丁不会改变情绪。调整基线值后，慢性尼古丁导致第8天（3.5 mg/天）CES-D评分显著下降，但在末次访视时恢复至安慰剂水平。这一恢复至基线水平与尼古丁给药从7 mg/天降至3.5 mg/天一致。还观察到通过Conners连续性能任务测量的反应抑制改善的类似趋势。报道的副作用是罕见的，minimal.Conclusion这些研究结果表明，烟碱受体系统在抑郁症的病理生理学的作用，烟碱类化合物治疗抑郁症症状进行评估。
Rationale Despite established links between nicotine dependence and depression, little research has examined the effects of nicotine on depression symptoms.Objective This study evaluated the acute and chronic effects of transdermal nicotine in nonsmokers with baseline depression symptoms during a 4-week, double-blind, placebo-controlled trial.Methods Nonsmokers with scores >= 10 on the Center for Epidemiological Studies Depression scale (CES-D) were recruited from the community. Mood and cognitive performance were measured at baseline ( day 0) and at 1, 8, 21, and 28 days. Participants were randomly assigned to wear a placebo or nicotine patch for 4 weeks (3.5 mg/day during weeks 1 and 4; 7 mg/day during weeks 2 and 3). The final sample consisted of 11 nonsmokers with a mean baseline CES-D score of 27.36 (SD=10.53).Results Salivary nicotine levels indicated the majority of participants were compliant with treatment. Acute nicotine did not alter mood. After adjusting for baseline values, chronic nicotine resulted in a significant decline in CES-D scores at day 8 (3.5 mg/day), but returned to placebo levels by the last visit. This return to baseline levels was coincident with a decrease in nicotine administration from 7 to 3.5 mg/day. A similar trend for improved response inhibition as measured by the Conners Continuous Performance Task was also observed. Reported side effects were infrequent and minimal.Conclusion These findings suggest a role for nicotinic receptor systems in the pathophysiology of depression and that nicotinic compounds should be evaluated for treating depression symptoms.